The scene in endocrinology clinics across India’s major metros has shifted significantly over the last three years. The consultation rooms are no longer filled only by patients managing long-term diabetes; instead, a new demographic has arrived. Younger professionals and health-conscious individuals are walking in with a specific request: Ozempic.
Driven by global trends and digital discourse, semaglutide has transitioned from a specialized pharmaceutical tool to a household name at a pace few pharmaceutical developments manage. While increased health awareness is generally welcomed, this rapid adoption has exposed a critical oversight in the patient care journey. As the buzz around weight loss and glucose control intensifies, Dr. Kamal B. Kapur and Dr. Samir Sud, Co-founders of Sharp Sight Eye Hospitals, argue that a vital part of the conversation is being left out. "Nobody is adequately talking about what these medications mean for the eyes," they caution.
The Unseen Link Between Metabolism and Vision
The typical patient profile for semaglutide therapy remains consistent: individuals navigating type 2 diabetes, significant obesity, or both. Coincidentally, this is the same group that has historically populated India’s retinal clinics. With diabetic retinopathy standing as a primary cause of preventable blindness in the country, the scale of the risk is immense.
Currently, approximately 101 million Indians live with diabetes, yet a substantial portion of this group has never had a proper retinal examination. When semaglutide is introduced, it brings blood sugar down meaningfully and sometimes quickly. However, this sudden metabolic shift is not without consequence.
The core clinical issue lies in the adaptation of retinal blood vessels. These vessels, having adjusted to high glucose environments over years, are not "neutral bystanders" when glycemic control suddenly tightens.
"It becomes newly relevant when a drug capable of producing this kind of rapid metabolic shift is being prescribed at scale across a population with widespread undetected retinopathy," explain Dr. Kapur and Dr. Sud.
Data from the SUSTAIN-6 trial documented cases where diabetic retinopathy transiently worsened following rapid glycemic improvement. While this phenomenon has been seen with intensive insulin therapy for years, the current scale of GLP-1 adoption makes baseline retinal assessments an essential clinical step.
Navigating the NAION Signal
In July 2024, the discussion gained further urgency following a paper in JAMA Ophthalmology regarding non-arteritic anterior ischaemic optic neuropathy, or NAION. This condition involves sudden vision loss from a disrupted blood supply to the optic nerve and often results in incomplete recovery.
The findings were striking: patients with type 2 diabetes on semaglutide had roughly four times the NAION risk compared to those on other medications. For those using the drug specifically for weight management, the observed figures were even more significant.
Dr. Kapur and Dr. Sud note that while NAION is rare and the study shows association rather than proof of causation, the medical community must remain vigilant. "A signal this specific, in a journal of this standing, affecting a patient population this large and growing, is not something ophthalmologists can quietly file away," they state. "It belongs in active clinical thinking now".
Closing the Referral Gap
The current reality of diabetes care in India often lacks interdisciplinary coordination. A patient may start Ozempic and see their HbA1c improve within months, yet at no point does anyone examine the retina.
"The pathway from an Ozempic prescription to a dilated fundus examination simply does not exist as a routine default in Indian clinical practice," the doctors observe. Solving this requires a cultural shift where prescribing physicians understand why retinal documentation matters and institutions stop treating coordination as optional.
A Strategic Look Toward the Future
The urgency of this conversation is tied to the expiration of semaglutide patents. As biosimilar versions enter the Indian market, cost barriers will fall, and the number of patients on GLP-1 therapy will look very different in three years.
Ophthalmic institutions are already building care pathways to accommodate this influx. They recognize that the clinical demand is coming, whether the infrastructure exists or not. For India’s eye care community, the goal is to use their clinical authority to ensure metabolic health does not come at the cost of sight.
As Dr. Kapur and Dr. Sud conclude, "The moment to use that authority is not after the problem has fully arrived. It is right now".
